Systemic Inflammatory Response Evaluation With the Use of Inhaled Anesthetic Sevoflurane During CPB
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02672345|
Recruitment Status : Completed
First Posted : February 3, 2016
Last Update Posted : June 23, 2020
|Condition or disease||Intervention/treatment|
|Inflammatory Response||Drug: Sevoflurane|
|Study Type :||Observational [Patient Registry]|
|Actual Enrollment :||100 participants|
|Target Follow-Up Duration:||1 Year|
|Official Title:||Systemic Inflammatory Response Evaluation With the Use of Inhaled Anesthetic Sevoflurane During CPB|
|Actual Study Start Date :||August 2016|
|Actual Primary Completion Date :||June 2020|
|Actual Study Completion Date :||June 2020|
Group of patients receiving sevorane during extracorporeal circulation period.
The Sevoflurane Group will receive between 0.7 and 1.5% of sevoflurane CAM only during CPB period. While Not Sevoflurane Group will receive only intravenous anesthetic agents.
Not Sevoflurane Group
Group of patients who did not receive the sevorane during extracorporeal circulation period.
- Reduction of systemic inflammatory response [ Time Frame: Through study completion, an average of 1 year ]Cytokines are assayed in both groups at 4 different times in order to check the impact of sevoflurane on the inflammatory response. The first one is the baseline of measurement with which the others are compared and all will be compared within and between groups.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02672345
|Thiago Augusto Azevedo Maranhão Cardoso|
|São Paulo, Brazil, 01423020|